Published in Bioorg Med Chem Lett on March 12, 2007
Targeting metabolic transformation for cancer therapy. Nat Rev Cancer (2010) 5.90
Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding. Chem Rev (2008) 2.27
Sources of protons and a role for bicarbonate in inhibitory feedback from horizontal cells to cones in Ambystoma tigrinum retina. J Physiol (2016) 0.91
Cyclooxygenase-2/carbonic anhydrase-IX up-regulation promotes invasive potential and hypoxia survival in colorectal cancer cells. J Cell Mol Med (2008) 0.90
Anticancer and antiviral sulfonamides. Curr Med Chem (2003) 2.75
Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov (2011) 2.45
Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett (2004) 2.33
Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents. Med Res Rev (2003) 2.33
Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost (2012) 2.24
Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett (2005) 2.24
Carbonic anhydrase inhibitors. Med Res Rev (2003) 2.09
Synthesis and antimalarial activity of novel chiral and achiral benzenesulfonamides bearing 1, 3, 4-oxadiazole moieties. J Enzyme Inhib Med Chem (2007) 2.00
Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget (2012) 1.77
Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res (2011) 1.76
Oxovanadium(IV) complexes of hydrazides: potential antifungal agents. J Enzyme Inhib Med Chem (2006) 1.73
Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem (2004) 1.72
Carbonic anhydrase in the scleractinian coral Stylophora pistillata: characterization, localization, and role in biomineralization. J Biol Chem (2008) 1.70
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A (2012) 1.65
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem (2004) 1.57
The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths. J Biol Chem (2009) 1.53
Isatin-derived antibacterial and antifungal compounds and their transition metal complexes. J Enzyme Inhib Med Chem (2004) 1.52
Carbonic anhydrases as targets for medicinal chemistry. Bioorg Med Chem (2007) 1.45
Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev (2012) 1.43
Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc Natl Acad Sci U S A (2009) 1.43
Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des (2005) 1.43
Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett (2004) 1.42
Design, synthesis, and evaluation of hydroxamic acid derivatives as promising agents for the management of Chagas disease. J Med Chem (2013) 1.42
Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. J Biol Chem (2008) 1.42
Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. J Biol Chem (2008) 1.40
Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle (2013) 1.34
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett (2003) 1.32
Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. Curr Med Chem (2007) 1.30
Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associated) and XIV with 4-substituted 3-pyridinesulfonamides. Eur J Med Chem (2010) 1.30
Anticonvulsant sulfonamides/sulfamates/sulfamides with carbonic anhydrase inhibitory activity: drug design and mechanism of action. Curr Pharm Des (2008) 1.29
Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci (2006) 1.27
Novel organometallic cationic ruthenium(II) pentamethylcyclopentadienyl benzenesulfonamide complexes targeted to inhibit carbonic anhydrase. J Biol Inorg Chem (2009) 1.26
Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic isozymes I and II, and the tumor-associated isozyme IX. Bioorg Med Chem Lett (2005) 1.26
Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX. Bioorg Med Chem Lett (2005) 1.25
2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem (2006) 1.25
Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res (2012) 1.21
Metal-Based Antibacterial and Antifungal Agents: Synthesis, Characterization, and In Vitro Biological Evaluation of Co(II), Cu(II), Ni(II), and Zn(II) Complexes With Amino Acid-Derived Compounds. Bioinorg Chem Appl (2006) 1.21
Sulfonamides and sulfonylated derivatives as anticancer agents. Curr Cancer Drug Targets (2002) 1.19
Characterization of CA XIII, a novel member of the carbonic anhydrase isozyme family. J Biol Chem (2003) 1.19
ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme. Chem Commun (Camb) (2006) 1.19
A new coral carbonic anhydrase in Stylophora pistillata. Mar Biotechnol (NY) (2011) 1.18
Epithelial carbonic anhydrases facilitate PCO2 and pH regulation in rat duodenal mucosa. J Physiol (2006) 1.17
Direct extracellular interaction between carbonic anhydrase IV and the human NBC1 sodium/bicarbonate co-transporter. Biochemistry (2003) 1.17
Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem (2010) 1.16
Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol (2011) 1.15
Root effect hemoglobin may have evolved to enhance general tissue oxygen delivery. Science (2013) 1.13
Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc (2009) 1.13
Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem (2011) 1.13
Sulfamates and their therapeutic potential. Med Res Rev (2005) 1.12
In vitro antibacterial, antifungal & cytotoxic activity of some isonicotinoylhydrazide Schiff's bases and their cobalt (II), copper (II), nickel (II) and zinc (II) complexes. J Enzyme Inhib Med Chem (2006) 1.11
Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators. J Med Chem (2011) 1.10
Bacterial protease inhibitors. Med Res Rev (2002) 1.10
Zinc complexes of benzothiazole-derived Schiff bases with antibacterial activity. J Enzyme Inhib Med Chem (2003) 1.10
Carbonic anhydrase IX: a new druggable target for the design of antitumor agents. Med Res Rev (2008) 1.09
New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treat Rev (2012) 1.08
Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem (2010) 1.06
Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors. J Med Chem (2011) 1.05
Phosphorylation of carbonic anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors. Cancer Res (2011) 1.05
Therapeutic potential of sulfamides as enzyme inhibitors. Med Res Rev (2006) 1.05